In any event, whether anti-PR3 antibodies have a direct pathogenic role in IBD and their connection with NET formation and neutrophil activation remains to be elucidated, and studies with this research goal are warranted, especially in the context of novel therapeutic strategies and patient stratification for treat-to-target. Here, PRTN3 is linked to inflammatory bowel disease.